Please login to the form below

Not currently logged in
Email:
Password:

EvaluatePharma

This page shows the latest EvaluatePharma news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk boosted by new type 2 diabetes launches

Novo Nordisk boosted by new type 2 diabetes launches

Ozempic has continued to grow since its  FDA approval, with EvaluatePharma predicting that the drug could become a $2.2bn product by 2022.

Latest news

More from news
Approximately 3 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    EvaluatePharma has predicted it could become a nearly $2.5bn product by 2024, providing it can also pick up approvals in AML and other indications like multiple myeloma.

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    The company is currently the pharma industry’s biggest player by revenue (earning $45.4bn in 2017), but analysts EvaluatePharma expect Novartis to overtake it by 2024.

  • Deal Watch May 2016 Deal Watch May 2016

    A recent analysis through 2015 made by EvaluatePharma shows that six of the top ten pharma companies will derive less than 20% of drug sales from products that were developed from

  • Pharma deals during February 2014 Pharma deals during February 2014

    The lustre of orphans continue. The orphan drug space continues-to-attract, not surprising given EvaluatePharma's estimate that orphan drug sales totalled $92bn in 2012, and will grow 8 per

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published...
NICE
Evolution or revolution: the latest review of NICE methods
By Leela Barham...
PRO
Integrating patient reported outcomes into clinical trials
How capturing the patient voice is unlocking medicines’ commercial potential...

Infographics